Search

Your search keyword '"Nagano, Hiroaki"' showing total 2,385 results
Start Over Author "Nagano, Hiroaki"
2,385 results on '"Nagano, Hiroaki"'

1. Esophagectomy for esophageal cancer in patients with a history of total pharyngolaryngectomy: a Japanese nationwide retrospective cohort study

Author

Okamura, Akihiko, Watanabe, Masayuki, Okui, Jun, Kuriyama, Kengo, Shiraishi, Osamu, Kurogochi, Takanori, Abe, Tetsuya, Sato, Hiroshi, Miyata, Hiroshi, Kawaguchi, Yoshihiko, Sato, Yusuke, Nagano, Hiroaki, Takeno, Shinsuke, Nakajima, Masanobu, Matsuo, Kentaro, Murakami, Kentaro, Takebayashi, Katsushi, Matsumoto, Sohei, Okumura, Tomoyuki, Kakeji, Yoshihiro, Kono, Koji, Oridate, Nobuhiko, Toh, Yasushi, Takeuchi, Hiroya, and Katori, Yukio

Published
2024
Full Text
View/download PDF

4. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Japan Clinical Oncology Group study JCOG2202 (LAPAN study)

Author

Ikenaga, Naoki, Hashimoto, Tadayoshi, Mizusawa, Junki, Kitabayashi, Ryo, Sano, Yusuke, Fukuda, Haruhiko, Nakata, Kohei, Shibuya, Kazuto, Kitahata, Yuji, Takada, Minoru, Kamei, Keiko, Kurahara, Hiroshi, Ban, Daisuke, Kobayashi, Shogo, Nagano, Hiroaki, Imamura, Hajime, Unno, Michiaki, Takahashi, Amane, Yagi, Shintaro, Wada, Hiroshi, Shirakawa, Hirofumi, Yamamoto, Naoto, Hirono, Seiko, Gotohda, Naoto, Hatano, Etsuro, Nakamura, Masafumi, and Ueno, Makoto

Published
2024
Full Text
View/download PDF

5. High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Author

Furuya, Kei, Nakajima, Masao, Tsunedomi, Ryouichi, Nakagami, Yuki, Xu, Ming, Matsui, Hiroto, Tokumitsu, Yukio, Shindo, Yoshitaro, Watanabe, Yusaku, Tomochika, Shinobu, Maeda, Noriko, Iida, Michihisa, Suzuki, Nobuaki, Takeda, Shigeru, Hazama, Shoichi, Ioka, Tatsuya, Hoshii, Yoshinobu, Ueno, Tomio, and Nagano, Hiroaki

Published
2024
Full Text
View/download PDF

7. Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma

Author

Saeki, Issei, Suehiro, Yutaka, Yamauchi, Yurika, Hoshida, Tomomi, Tanabe, Norikazu, Oono, Takashi, Kawamoto, Daiki, Nishimura, Tatsuro, Matsumoto, Toshihiko, Ishikawa, Tsuyoshi, Shimokawa, Mototsugu, Tamori, Akihiro, Kawada, Norifumi, Tamai, Yasuyuki, Iwasa, Motoh, Nakagawa, Hayato, Nagano, Hiroaki, Takami, Taro, and Yamasaki, Takahiro

Published
2023
Full Text
View/download PDF

8. Novel Artificial Intelligence Combining Convolutional Neural Network and Support Vector Machine to Predict Colorectal Cancer Prognosis and Mutational Signatures From Hematoxylin and Eosin Images

Author

Mazaki, Junichi, Umezu, Tomohiro, Saito, Akira, Katsumata, Kenji, Fujita, Koji, Hashimoto, Mikihiro, Kobayashi, Masaharu, Udo, Ryutaro, Kasahara, Kenta, Kuwabara, Hiroshi, Ishizaki, Tetsuo, Matsubayashi, Jun, Nagao, Toshitaka, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Tanaka, Takashi, Tsuchida, Akihiko, Nagakawa, Yuichi, and Kuroda, Masahiko

Published
2024
Full Text
View/download PDF

9. Differentiating primary central nervous system lymphoma from glioblastoma by time-dependent diffusion using oscillating gradient

Author

Kamimura, Kiyohisa, Nakano, Tsubasa, Hasegawa, Tomohito, Nakajo, Masanori, Yamada, Chihiro, Kamimura, Yoshiki, Akune, Kentaro, Ejima, Fumitaka, Ayukawa, Takuro, Nagano, Hiroaki, Takumi, Koji, Nakajo, Masatoyo, Higa, Nayuta, Yonezawa, Hajime, Hanaya, Ryosuke, Kirishima, Mari, Tanimoto, Akihide, Iwanaga, Takashi, Imai, Hiroshi, Feiweier, Thorsten, and Yoshiura, Takashi

Published
2023
Full Text
View/download PDF

14. IL-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal Cancer

Author

Yamamoto, Tsunenori, Tsunedomi, Ryouichi, Nakajima, Masao, Suzuki, Nobuaki, Yoshida, Shin, Tomochika, Shinobu, Xu, Ming, Nakagami, Yuki, Matsui, Hiroto, Tokumitsu, Yukio, Shindo, Yoshitaro, Watanabe, Yusaku, Iida, Michihisa, Takeda, Shigeru, Hazama, Shoichi, Tanabe, Tsuyoshi, Ioka, Tatsuya, Hoshii, Yoshinobu, Kiyota, Akifumi, Takizawa, Hitoshi, Kawakami, Yutaka, Ueno, Tomio, and Nagano, Hiroaki

Published
2023
Full Text
View/download PDF

15. An Analysis of 10,000 Cases of Living Donor Liver Transplantation in Japan: Special Reference to the Graft-Versus-Recipient Weight Ratio and Donor Age

Author

Eguchi, Susumu, Umeshita, Koji, Soejima, Yuji, Eguchi, Hidetoshi, Egawa, Hiroto, Fukumoto, Takumi, Haga, Hironori, Hasegawa, Kiyoshi, Kasahara, Mureo, Nagano, Hiroaki, Takada, Yasutsugu, Tokushige, Katsutoshi, Ueda, Yoshihide, Mochida, Satoshi, Matsushima, Hajime, Adachi, Tomohiko, and Ohdan, Hideki

Published
2024
Full Text
View/download PDF

16. Impact of the hospital volume and setting on postoperative complications of surgery for gastroenterological cancers in a regional area of Western Japan

Author

Kunisawa, Susumu, Ishida, Haku, Ikai, Hiroshi, Nagano, Hiroaki, Fujiwara, Toshiyoshi, Ohdan, Hideki, Fujiwara, Yoshiyuki, Tajima, Yoshitsugu, Ueno, Tomio, Fujiwara, Yoshinori, Shimada, Mitsuo, Suzuki, Yasuyuki, Watanabe, Yuji, Hanazaki, Kazuhiro, Kakeji, Yoshihiro, Kumamaru, Hiraku, Takahashi, Arata, Miyata, Hiroaki, and Imanaka, Yuichi

Published
2023
Full Text
View/download PDF

17. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement

Author

Ikenaga, Naoki, Miyasaka, Yoshihiro, Ohtsuka, Takao, Nakata, Kohei, Adachi, Tomohiko, Eguchi, Susumu, Nishihara, Kazuyoshi, Inomata, Masafumi, Kurahara, Hiroshi, Hisaka, Toru, Baba, Hideo, Nagano, Hiroaki, Ueki, Toshiharu, Noshiro, Hirokazu, Tokunaga, Shoji, Ishigami, Kousei, and Nakamura, Masafumi

Published
2023
Full Text
View/download PDF

19. Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine

Author

Shiota (Sato), Yomogi, Elbadawy, Mohamed, Suzuki, Kazuhiko, Tsunedomi, Ryouichi, Nagano, Hiroaki, Ishihara, Yusuke, Yamamoto, Haru, Azakami, Daigo, Uchide, Tsuyoshi, Fukushima, Ryuji, Tanaka, Ryo, Yoshida, Tomohiko, Mori, Takuya, Abugomaa, Amira, Kaneda, Masahiro, Yamawaki, Hideyuki, Shinohara, Yuta, Aboubakr, Mohamed, El-Asrag, Mohamed E., Usui, Tatsuya, and Sasaki, Kazuaki

Published
2023
Full Text
View/download PDF

20. Long-Term Feasibility of Rescue Reconstruction for Isolated Bile Ducts With Using Cystic Duct in Living Donor Liver Transplantation

Author

Kubo, Masahiko, Tomimaru, Yoshito, Gotoh, Kunihito, Kobayashi, Shogo, Marukawa, Daiki, Sasaki, Kazuki, Iwagami, Yoshifumi, Yamada, Daisaku, Akita, Hirofumi, Noda, Takehiro, Takahashi, Hidenori, Asaoka, Tadafumi, Tanemura, Masahiro, Marubashi, Shigeru, Nagano, Hiroaki, Dono, Keizo, Doki, Yuichiro, and Eguchi, Hidetoshi

Published
2023
Full Text
View/download PDF

24. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Author

Okamura, Keiya, Kawamoto, Yasuyuki, Katanuma, Akio, Unno, Michiaki, Shirakawa, Hirofumi, Yamaguchi, Hironori, Takahashi, Amane, Ikeda, Masafumi, Yanagibashi, Hiroo, Kato, Naoya, Okusaka, Takuji, Sakamoto, Yoshihiro, Kojima, Yasushi, Higuchi, Ryota, Sasahira, Naoki, Sano, Keiji, Nakagohri, Toshio, Sunakawa, Yu, Morinaga, Soichiro, Kumamoto, Yusuke, Sugimori, Kazuya, Nomura, Tatsuya, Shibuya, Kazuto, Makino, Isamu, Yamazaki, Kentaro, Mizuno, Nobumasa, Kamata, Ken, Wada, Hiroshi, Gotoh, Kunihito, Sekimoto, Mitsugu, Ajiki, Tetsuo, Nakamura, Ikuo, Miki, Ikuya, Nagano, Hiroaki, Ohta, Koji, Okabayashi, Takehiro, Furukawa, Masayuki, Fujimori, Nao, Nakachi, Kohei, Konishi, Masaru, Nomura, Shogo, Katayama, Hiroshi, Kataoka, Tomoko, Todaka, Akiko, Yanagimoto, Hiroaki, Kobayashi, Shogo, Shimada, Kazuaki, Takahashi, Yu, Shimizu, Yasuhiro, Ueno, Makoto, Ishii, Hiroshi, and Furuse, Junji

Published
2023
Full Text
View/download PDF

25. Interferon signaling and hypercytokinemia-related gene expression in the blood of antidepressant non-responders

Author

Yamagata, Hirotaka, Tsunedomi, Ryouichi, Kamishikiryo, Toshiharu, Kobayashi, Ayumi, Seki, Tomoe, Kobayashi, Masaaki, Hagiwara, Kosuke, Yamada, Norihiro, Chen, Chong, Uchida, Shusaku, Ogihara, Hiroyuki, Hamamoto, Yoshihiko, Okada, Go, Fuchikami, Manabu, Iga, Jun-ichi, Numata, Shusuke, Kinoshita, Makoto, Kato, Takahiro A., Hashimoto, Ryota, Nagano, Hiroaki, Ueno, Shuichi, Okamoto, Yasumasa, Ohmori, Tetsuro, and Nakagawa, Shin

Published
2023
Full Text
View/download PDF

28. Supplementary Methods from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

29. Table S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

30. Figure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

31. Data from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Author

Mikami, Hirofumi, primary, Feng, Shu, primary, Matsuda, Yutaka, primary, Ishii, Shinya, primary, Naoi, Sotaro, primary, Azuma, Yumiko, primary, Nagano, Hiroaki, primary, Asanuma, Kentaro, primary, Kayukawa, Yoko, primary, Tsunenari, Toshiaki, primary, Kamikawaji, Shogo, primary, Iwabuchi, Ryutaro, primary, Shinozuka, Junko, primary, Yamazaki, Masaki, primary, Kuroi, Haruka, primary, Ho, Samantha Shu Wen, primary, Gan, Siok Wan, primary, Chichili, Priyanka, primary, Pang, Chai Ling, primary, Yeo, Chiew Ying, primary, Shimizu, Shun, primary, Hironiwa, Naoka, primary, Kinoshita, Yasuko, primary, Shimizu, Yuichiro, primary, Sakamoto, Akihisa, primary, Muraoka, Masaru, primary, Takahashi, Noriyuki, primary, Kawa, Tatsuya, primary, Shiraiwa, Hirotake, primary, Mimoto, Futa, primary, Kashima, Kenji, primary, Kamata-Sakurai, Mika, primary, Ishikawa, Shumpei, primary, Aburatani, Hiroyuki, primary, Kitazawa, Takehisa, primary, and Igawa, Tomoyuki, primary

Published
2024
Full Text
View/download PDF

33. Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective study

Author

Ono, Shinichiro, Adachi, Tomohiko, Ohtsuka, Takao, Kimura, Ryuichiro, Nishihara, Kazuyoshi, Watanabe, Yusuke, Nagano, Hiroaki, Tokumitsu, Yukio, Nanashima, Atsushi, Imamura, Naoya, Baba, Hideo, Chikamoto, Akira, Inomata, Masafumi, Hirashita, Teijiro, Furukawa, Masayuki, Idichi, Tetsuya, Shinchi, Hiroyuki, Maruyama, Yuichiro, Nakamura, Masafumi, and Eguchi, Susumu

Published
2022
Full Text
View/download PDF

34. ASO Visual Abstract: Interleukin-6 Levels Correlate with Prognosis and Immunosuppressive Stromal Cells in Patients with Colorectal Cancer

Author

Yamamoto, Tsunenori, Tsunedomi, Ryouichi, Nakajima, Masao, Suzuki, Nobuaki, Yoshida, Shin, Tomochika, Shinobu, Xu, Ming, Nakagami, Yuki, Matsui, Hiroto, Tokumitsu, Yukio, Shindo, Yoshitaro, Watanabe, Yusaku, Iida, Michihisa, Takeda, Shigeru, Hazama, Shoichi, Tanabe, Tsuyoshi, Ioka, Tatsuya, Hoshii, Yoshinobu, Kiyota, Akifumi, Takizawa, Hitoshi, Kawakami, Yutaka, Ueno, Tomio, and Nagano, Hiroaki

Published
2023
Full Text
View/download PDF

37. CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule

Author

Nakagami, Yuki, Hazama, Shoichi, Suzuki, Nobuaki, Yoshida, Shin, Tomochika, Shinobu, Matsui, Hiroto, Shindo, Yoshitaro, Tokumitsu, Yukio, Matsukuma, Satoshi, Watanabe, Yusaku, Iida, Michihisa, Tsunedomi, Ryouichi, Takeda, Shigeru, Fujita, Tomonobu, Kawakami, Yutaka, Ogihara, Hiroyuki, Hamamoto, Yoshihiko, Ioka, Tatsuya, Tanabe, Tsuyoshi, Ueno, Tomio, and Nagano, Hiroaki

Published
2022
Full Text
View/download PDF

40. ASO Visual Abstract: A Prospective, Multicenter, Phase II, Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement

Author

Ikenaga, Naoki, Miyasaka, Yoshihiro, Ohtsuka, Takao, Nakata, Kohei, Adachi, Tomohiko, Eguchi, Susumu, Nishihara, Kazuyoshi, Inomata, Masafumi, Kurahara, Hiroshi, Hisaka, Toru, Baba, Hideo, Nagano, Hiroaki, Ueki, Toshiharu, Noshiro, Hirokazu, Tokunaga, Shoji, Ishigami, Kousei, and Nakamura, Masafumi

Published
2023
Full Text
View/download PDF

41. Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer.

Author

Shindo, Yoshitaro, Ioka, Tatsuya, Tokumitsu, Yukio, Matsui, Hiroto, Nakajima, Masao, Kimura, Yuta, Watanabe, Yusaku, Tomochika, Shinobu, Nakagami, Yuki, Tsunedomi, Ryouichi, Iida, Michihisa, Takahashi, Hidenori, and Nagano, Hiroaki

Subjects
PATIENT safety, PILOT projects, ASPARTATE aminotransferase, TREATMENT effectiveness, RETROSPECTIVE studies, PANCREATIC tumors, COMBINED modality therapy, ALANINE aminotransferase, NAUSEA, OLD age
Abstract

Simple Summary: Neoadjuvant chemotherapy (NAC) is effective in improving the prognosis of patients with resectable and borderline resectable pancreatic cancer (PC). A modified FOLFIRINOX (mFOLFIRINOX) regimen is widely used as the standard therapy. However, owing to its toxicity, it is not applied in patients older than 75 years. Furthermore, elderly patients often have concomitant conditions and are at high risk for adverse effects associated with chemotherapy. Given the rapid increase in the number of elderly patients, it is necessary to determine whether NAC can be performed in both non-elderly and elderly patients. Thus, in this study, we investigated the safety and feasibility of neoadjuvant mFOLFIRINOX in elderly patients with PC. We found that the perioperative and postoperative outcomes of elderly patients who received neoadjuvant mFOLFIRINOX were comparable to those of non-elderly patients. The optimal treatment strategy for neoadjuvant chemotherapy in elderly patients with pancreatic cancer (PC) remains unclear. Hence, this study was aimed at evaluating the safety and feasibility of neoadjuvant-modified FOLFIRINOX (mFOLFIRINOX) in elderly patients with PC. We retrospectively collected data from 62 patients who received neoadjuvant mFOLFIRINOX between May 2015 and October 2023 and comparatively analyzed the clinicopathological data and outcomes between the non-elderly group (age: <75 years) and elderly group (age: >75 years). The non-elderly and elderly groups comprised 39 and 23 patients, respectively. Although elevated levels of aspartate aminotransferase (p = 0.0173) and alanine aminotransferase (p = 0.0378) and nausea (p = 0.0177) were more frequent in the elderly group, the incidence of severe adverse events was similar between the groups. Intergroup differences in resection rate (p = 0.3381), postoperative severe complication rates (p = 0.2450), and postoperative hospital stay (p = 0.3496) were not significant. Furthermore, no significant intergroup differences were found in survival in either the whole or the resection cohorts. The perioperative and postoperative outcomes of elderly patients treated with neoadjuvant mFOLFIRINOX were comparable with those of non-elderly patients. Neoadjuvant mFOLFIRINOX should be considered a feasible option for elderly patients with PC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Conversion surgery for initially unresectable locally advanced biliary tract cancer: A multicenter collaborative study conducted in Japan and Korea.

Author

Yabushita, Yasuhiro, Park, Joon Seong, Yoon, Yoo‐Seok, Ohtsuka, Masayuki, Kwon, Wooil, Choi, Gi Hong, Imamura, Masafumi, Matsumoto, Ippei, Mizuno, Shugo, Matsuyama, Ryusei, Sakata, Jun, Hayashi, Hiromitsu, Takeda, Yutaka, Katagiri, Satoshi, Sugawara, Toshitaka, Kobayashi, Shogo, Kawasaki, Yota, Nagano, Hiroaki, Murase, Katsutoshi, and Kim, Hyung Sun

Abstract

Background: Although surgical resection is the only curative treatment for biliary tract cancer, in some cases, the disease is diagnosed as unresectable at initial presentation. There are few reports of conversion surgery after the initial treatment for unresectable locally advanced biliary tract cancer. This study aimed to evaluate the efficacy and safety of conversion surgery in patients with initially unresectable locally advanced biliary tract cancer. Methods: We retrospectively collected clinical data from groups of patients in multiple centers belonging to the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery and Korean Association of Hepato‐Biliary‐Pancreatic Surgery. We analyzed two groups of prognostic factors (pretreatment and surgical factors) and their relation to the treatment outcomes. Results: A total of 56 patients with initially unresectable locally advanced biliary tract cancer were enrolled in this study of which 55 (98.2%) patients received chemotherapy, and 16 (28.6%) patients received additional radiation therapy. The median time from the start of the initial treatment to resection was 6.4 months. Severe postoperative complications of Clavien‐Dindo grade III or higher occurred in 34 patients (60.7%), and postoperative mortality occurred in five patients (8.9%). Postoperative histological results revealed CR in eight patients (14.3%). The median survival time from the start of the initial treatment in all 56 patients who underwent conversion surgery was 37.7 months, the 3‐year survival rate was 53.9%, and the 5‐year survival rate was 39.1%. Conclusions: Conversion surgery for initially unresectable locally advanced biliary tract cancer may lead to longer survival in selected patients. However, more precise preoperative safety evaluation and careful postoperative management are required. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Prognostic significance of lymph node metastasis in pancreatic tail cancer: A multicenter retrospective study.

Author

Hirashita, Teijiro, Ikenaga, Naoki, Nakata, Kohei, Nakamura, Masafumi, Kurahara, Hiroshi, Ohtsuka, Takao, Tatsuguchi, Takaaki, Nishihara, Kazuyoshi, Hayashi, Hiromitsu, Nakagawa, Shigeki, Ide, Takao, Noshiro, Hirokazu, Adachi, Tomohiko, Eguchi, Susumu, Miyoshi, Atsushi, Kohi, Shiro, Nanashima, Atsushi, Nagano, Hiroaki, Takatsuki, Mitsuhisa, and Inomata, Masafumi

Subjects
LYMPHATIC metastasis, PANCREATIC cancer, PANCREATIC tumors, SPLENIC artery, HEPATIC artery, CELIAC artery, PANCREATIC surgery, PANCREATECTOMY
Abstract

Background: Distal pancreatectomy (DP) with lymph node (LN) dissection is the standard procedure for pancreatic ductal adenocarcinoma of the tail (Pt‐PDAC). However, the optimal surgery including extent of LN dissection is still being debated. The present study investigated the incidence and prognostic impact of LN metastasis on patients suffering from Pt‐PDAC. Patients and method: This multicenter, retrospective study involved 163 patients who underwent DP for resectable Pt‐PDAC at 12 institutions between 2013 and 2017. The frequency of LN metastasis and the effect of LN dissection on Pt‐PDAC prognosis were investigated. Results: There were high incidences of metastases to the LNs along the splenic artery in the patients with Pt‐PDAC (39%). The rate of metastases in the LNs along the common hepatic, left gastric, and celiac arteries were low, and the therapeutic index for these LNs was zero. In pancreatic tail cancer located more distally, there were no metastases to the LNs along the common hepatic artery. Multivariate analysis revealed that tumor size was the only independent factor related to recurrence‐free survival (HR = 2.01, 95% CI = 1.33–3.05, p = 0.001). The level of pancreas division and LN dissection along the common hepatic artery did not affect the site of tumor recurrence or recurrence‐free survival. Conclusions: LN dissection along the hepatic artery for Pt‐PDAC has little significance. Distal pancreatic transection may be acceptable in terms of oncological safety, but further examination of short‐term outcomes and preservation of pancreatic function is required. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical Study Group of Osaka University, Hepato‐Biliary‐Pancreatic Group

Author

Kobayashi, Shogo, Tomokuni, Akira, Takeda, Yutaka, Wada, Hiroshi, Katsura, Yoshiteru, Hashimoto, Kazuhiko, Tomimaru, Yoshito, Asaoka, Tadafumi, Yamada, Terumasa, Tsujie, Masanori, Noda, Takehiro, Morita, Satoshi, Nagano, Hiroaki, Mori, Masaki, Doki, Yuichiro, and Eguchi, Hidetoshi

Subjects
CHEMOEMBOLIZATION, HEPATOCELLULAR carcinoma, MINIMALLY invasive procedures, HEPATIC veins, OVERALL survival, SURGERY
Abstract

Aim: Neoadjuvant transcatheter arterial chemoembolization (TACE) for large tumors is controversial, especially in the minimally invasive surgery era. The aim of this study was to compare features between groups treated with neoadjuvant TACE followed by surgery (TACE + surgery) or upfront surgery for hepatocellular carcinoma >5 cm. Methods: In this exploratory, multicenter, randomized phase I study, the primary measure was 2‐year disease‐free survival (DFS). Secondary measures were resection rate, necrosis rate by TACE, 2‐year overall survival, and site of recurrence. A total of 30 patients were randomly allocated to each arm. Results: The two arms did not differ in patient characteristics. The median time to surgery from randomization was 48 days for TACE + surgery and 29 for surgery only (p < 0.001). Postoperative morbidities did not differ between arms. The 2‐year DFS, overall survival, and resection rates were 56.7%, 80.0%, and 93.3%, respectively, in the TACE + surgery arm, and 56.1%, 89.9%, and 90.0% in the upfront surgery arm. Minimally invasive surgery was carried out in 35.7% in the TACE + surgery arm and in 29.6% in the upfront surgery arm. The median necrosis rate by TACE was 90.0%. In resected specimens, invasion to the hepatic vein was less with TACE + surgery (3.6% vs. 22.2%, p = 0.0380). In cases of 100% necrosis with TACE, 2‐year DFS was 100%. Site of recurrence did not differ between groups. Conclusion: Neoadjuvant TACE did not improve 2‐year DFS, and neoadjuvant TACE allowed delay of surgical treatment without increased morbidity and cancer progress. Clinical trial registration: UMIN: 000005241. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?

Author

Hirono, Seiko, primary, Higuchi, Ryota, additional, Honda, Goro, additional, Nara, Satoshi, additional, Esaki, Minoru, additional, Gotohda, Naoto, additional, Takami, Hideki, additional, Unno, Michiaki, additional, Sugiura, Teiichi, additional, Ohtsuka, Masayuki, additional, Shimizu, Yasuhiro, additional, Matsumoto, Ippei, additional, Kin, Toshifumi, additional, Isayama, Hiroyuki, additional, Hashimoto, Daisuke, additional, Seyama, Yasuji, additional, Nagano, Hiroaki, additional, Hakamada, Kenichi, additional, Hirano, Satoshi, additional, Nagakawa, Yuichi, additional, Mizuno, Shugo, additional, Takahashi, Hidenori, additional, Shibuya, Kazuto, additional, Sasanuma, Hideki, additional, Aoki, Taku, additional, Kohara, Yuichiro, additional, Rikiyama, Toshiki, additional, Nakamura, Masafumi, additional, Endo, Itaru, additional, Sakamoto, Yoshihiro, additional, Horiguchi, Akihiko, additional, Hatori, Takashi, additional, Akita, Hirofumi, additional, Ueki, Toshiharu, additional, Idichi, Tetsuya, additional, Hanada, Keiji, additional, Suzuki, Shuji, additional, Okano, Keiichi, additional, Maehira, Hiromitsu, additional, Motoi, Fuyuhiko, additional, Fujino, Yasuhiro, additional, Tanno, Satoshi, additional, Yanagisawa, Akio, additional, Takeyama, Yoshifumi, additional, Okazaki, Kazuichi, additional, Satoi, Sohei, additional, and Yamaue, Hiroki, additional

Published
2024
Full Text
View/download PDF

48. Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH

Author

KONDO, JUNYA, primary, YOSHINO, SHIGEFUMI, additional, IIDA, MICHIHISA, additional, TAKEDA, SHIGERU, additional, NAKASHIMA, CHIYO, additional, WATANABE, YUSAKU, additional, NISHIYAMA, MITSUO, additional, TOKUMITSU, YUKIO, additional, SHINDO, YOSHITARO, additional, NISHIMURA, TAKU, additional, SUZUKI, NOBUAKI, additional, HOSHII, YOSHINOBU, additional, ITOH, HIROSHI, additional, and NAGANO, HIROAKI, additional

Published
2024
Full Text
View/download PDF

49. Effect of Paxillin Expression and Phosphorylation on Colorectal Cancer Prognosis and Metastasis

Author

ZHENG, HUANYU, primary, TSUNEDOMI, RYOUICHI, additional, XU, MING, additional, ZHANG, YING, additional, KISHI, HIROKO, additional, KOBAYASHI, SEI, additional, TOMOCHIKA, SHINOBU, additional, NAKAJIMA, MASAO, additional, MATSUI, HIROTO, additional, TOKUMITSU, YUKIO, additional, SHINDO, YOSHITARO, additional, IIDA, MICHIHISA, additional, IOKA, TATSUYA, additional, and NAGANO, HIROAKI, additional

Published
2024
Full Text
View/download PDF

50. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).

Author

Furuse, Junji, primary, Jiang, Bo, additional, Kuwahara, Takamichi, additional, Satoh, Taroh, additional, Ma, Xuelei, additional, Yan, Sheng, additional, Zhao, Hai-Tao, additional, Ikeda, Masafumi, additional, Cui, Tongjian, additional, Sasaki, Takashi, additional, Meng, Zhiqiang, additional, Nakai, Yousuke, additional, Ueno, Makoto, additional, Komatsu, Yoshito, additional, Nagano, Hiroaki, additional, Morizane, Chigusa, additional, Funasaka, Setsuo, additional, Ikezawa, Hiroki, additional, Nakada, Takuya, additional, and Shen, Lin, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results